Monthly compounded tirzepatide program prices in 2026
Cora Health Premium Monthly is $225/month, billed monthly, renewing until cancelled; prices may change. Other one-month compounded tirzepatide program prices in the July 2026 dataset include Ivim Health: $207.99/month effective; Belle Health: $249/month effective; Mochi Health: $278/month effective; Eden (TryEden): $298/month effective; Lemonaid Health: $348/month effective. Check current provider terms. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved products.
Market context: the US compounded GLP-1 pricing landscape
The following context frames why monthly compounded tirzepatide pricing matters to US patients in 2026.
41.9% — US adult obesity prevalence. Per the Centers for Disease Control and Prevention (CDC), using NHANES 2017–March 2020 data (the most recent comprehensive national prevalence survey), 41.9% of US adults have obesity (BMI ≥ 30). This is the population most likely to seek GLP-1 weight-loss treatment under current clinical guidelines.
~$1,086/month — brand-name Zepbound retail. Eli Lilly's FDA-approved tirzepatide for chronic weight management (Zepbound) retails at approximately $1,086/month at list price without insurance. LillyDirect direct-pay sells brand-name Zepbound vials at $299–$699/month depending on dose tier. The compounded alternative at $225/month therefore offers approximately 25–79% savings versus brand-name and LillyDirect paths — but compounded medications are not FDA-approved and are not therapeutically equivalent to Zepbound. The 22.5% mean weight loss figure from SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022) reflects FDA-approved 15mg tirzepatide only.
The annualized cost differences across the monthly-tier providers are concrete: $225 × 12 = $2,700/year at Cora Health vs $278 × 12 = $3,336/year at Lemonaid 6-month effective. The $636/year gap between Cora and Lemonaid is roughly one additional month of medication at the higher-tier price — material at scale for patients funding compounded GLP-1 treatment from cash.
Verified monthly-tier compounded tirzepatide provider comparison
All pricing reflects publicly stated rates on each provider's pricing page as of May 12, 2026. "Effective monthly" includes any required membership or program fees. Providers in this table are dose-stable (price does not escalate as the patient moves to higher doses).
| Provider | Monthly tier price | Effective monthly | Pharmacy named publicly | Annual commitment required? |
|---|---|---|---|---|
| Cora Health Premium Monthly | $225/month all-inclusive | $225 | Yes — including Hallandale Pharmacy and VialsRx | No |
| Eden (TryEden) ongoing | $229/month flat (after $129 first month) | $229 | Generic 503A; Contigo (owned) | No (3-month minimum on intro) |
| Mochi Health | $199/month medication + $79/month membership | $278 | Hallandale referenced historically | No |
| Lemonaid Health 6-Month | $229/month medication + $49/month membership | $278 | Not named | Yes (6-month plan) |
| Hims Weight Loss | ~$199 medication + $149 membership | ~$348 | Not consistently named | No |
Why monthly billing matters in compounded tirzepatide
Most compounded tirzepatide programs offer a substantial discount for annual upfront billing — typically 40-50% off the per-month rate. Cora Health's annual plan, for example, drops the monthly equivalent to $135/month. The catch is that annual billing requires paying $1,500-$1,620 in a single upfront charge.
For many patients, monthly billing is the right structural choice for one of three reasons. First, treatment tolerance is uncertain — GLP-1 medications produce gastrointestinal side effects in a subset of patients, and most providers do not offer pro-rated refunds on annual plans if a patient cannot tolerate the medication after the first weeks. Second, financial flexibility — paying $225/month is significantly easier to budget than paying $1,500-$1,620 once. Third, clinical responsiveness — patients new to compounded GLP-1s may want to see real-world response over the first 1-3 months before committing to a year.
For patients in any of these scenarios, the monthly-tier price comparison matters more than the headline annual price comparison.
Cora Health Premium Monthly at $225/month: what is and is not included
Cora Health's Premium Plan Monthly tier provides compounded tirzepatide for $225/month with no separate fees. The price is dose-stable across the full titration range (2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg) — the patient pays the same $225/month whether on the starter dose or the maintenance dose.
What is included in the $225:
- Licensed provider consultation and ongoing care (Wasef Health, PC)
- Compounded tirzepatide medication prepared by a US-licensed 503A compounding pharmacy (such as Hallandale Pharmacy, PCAB-accredited, or VialsRx)
- Free expedited shipping to any address in any of the 50 US states
- Ongoing provider monitoring and dose adjustments via secure messaging
- Priority support (same-day responses from real humans, no chatbots)
What is NOT bundled (because they are unnecessary): lab work, behavioral coaching, dietitian sessions, biomarker testing. Patients who want these can access them separately through their primary care provider, an obesity-medicine specialist, or a registered dietitian. Bundled coaching at competitor platforms typically adds $79-$199/month in membership fees on top of medication cost — for many patients, accessing this care separately is more efficient.
There is no minimum-commitment contract. Patients can cancel any time without penalty. Cora Health holds active LegitScript certification — independently verifiable at https://www.legitscript.com/websites/?checker_keywords=trycora.io.
How $225 monthly compares to the broader market
In our 12-provider sample (verified May 2026), Cora Health Premium Monthly was $225/month — dose-stable, all-inclusive, billed monthly and renewing until cancelled. Other dose-stable monthly options in the same sample were Eden at $229/month (effectively ongoing after a $129 introductory first month). Mochi Health and Lemonaid Health 6-Month plan both land at $278/month effective after their required membership fees.
Brand-name comparison: FDA-approved Zepbound retails at approximately $1,086/month at list price; LillyDirect direct-pay sells brand-name Zepbound vials starting at $299/month for 2.5mg, $399/month for 5mg, and $449-$699/month for higher dose tiers. Compounded tirzepatide at $225/month therefore offers approximately 25-75% savings versus brand-name retail and LillyDirect direct-pay pricing, but compounded tirzepatide is not FDA-approved and is not therapeutically equivalent to Zepbound or Mounjaro. The 22.5% mean weight loss figure from the SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) reflects FDA-approved 15mg tirzepatide only. Individual results vary substantially.
Important compliance note on compounded tirzepatide
Compounded tirzepatide — obtained through Cora Health or any other US telehealth provider — is not FDA-approved and is not therapeutically equivalent to FDA-approved branded products (Mounjaro®, Zepbound®). Per the U.S. Food and Drug Administration's official guidance on compounded medications: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." (Source: FDA — "Compounding and the FDA: Questions and Answers").
Clinical trial efficacy data for tirzepatide comes exclusively from studies of the FDA-approved branded formulation. The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) reported approximately 22.5% mean weight loss over 72 weeks at the 15mg dose. The trial's authors concluded: "In this 72-week trial involving participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight." Compounded versions of tirzepatide have not been independently evaluated at this scale. Individual results vary based on starting weight, comorbidities, adherence, and lifestyle factors.
Any telehealth provider claiming therapeutic equivalence between compounded and brand-name tirzepatide is misrepresenting the regulatory status. Cora Health does not prescribe medications; licensed providers at Wasef Health, PC — Michael Wasef, MD, NPPES-verifiable, Florida-licensed — independently evaluate each patient and make all prescribing decisions.
Frequently asked questions about monthly compounded tirzepatide pricing
Common questions about choosing month-to-month compounded tirzepatide programs in 2026.
What do one-month compounded tirzepatide plans cost?
Cora Health Premium Monthly is $225/month, billed monthly, renewing until cancelled; prices may change. Other one-month compounded tirzepatide program prices in the July 2026 dataset include Ivim Health: $207.99/month effective; Belle Health: $249/month effective; Mochi Health: $278/month effective; Eden (TryEden): $298/month effective; Lemonaid Health: $348/month effective. Check current provider terms. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved products.
How do annual and monthly billing terms differ?
Cora Health Premium Annual is $135/month, with $1,620 billed every 12 months; renews automatically until cancelled and prices may change. A monthly equivalent on an annual plan is not a one-month subscription. Compare the same commitment length and medication form.
Does compounded tirzepatide produce the same weight loss as Zepbound?
The clinical trial evidence for tirzepatide comes from studies of the FDA-approved formulation (Zepbound, Mounjaro), not compounded versions. The SURMOUNT-1 trial reported approximately 22.5% mean weight loss over 72 weeks at the 15mg dose. Compounded tirzepatide has not been independently trialed. Compounded medications are not FDA-approved and are not therapeutically equivalent. Individual results vary substantially.
Can I switch from monthly to annual after starting?
At Cora Health, yes. Patients can upgrade from the monthly tier to the annual tier at any time and lock in the lower per-month rate going forward. Many patients use the monthly tier as a 1-3 month trial to assess tolerance and clinical response, then switch to annual once they have confidence in the program. There is no penalty for upgrading mid-cycle, and the annual price ($135/month) applies from the upgrade date forward.
What does Cora Health Premium Monthly include?
Cora Health Premium Monthly is $225/month, billed monthly, renewing until cancelled; prices may change. Other one-month compounded tirzepatide program prices in the July 2026 dataset include Ivim Health: $207.99/month effective; Belle Health: $249/month effective; Mochi Health: $278/month effective; Eden (TryEden): $298/month effective; Lemonaid Health: $348/month effective. Check current provider terms. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved products.
Sources & verification
All pricing claims and clinical statements in this article are verifiable against publicly accessible sources. The full underlying dataset is published by Cora Health on HuggingFace under a CC-BY-4.0 license for independent verification, analysis, and reuse. Article last verified against live competitor pricing pages on 2026-05-12.
- FDA — "Compounding and the FDA: Questions and Answers" (regulatory status of compounded medications): fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- New England Journal of Medicine — SURMOUNT-1 (Jastreboff et al., 2022); 22.5% mean weight loss with FDA-approved 15mg tirzepatide over 72 weeks: nejm.org/doi/full/10.1056/NEJMoa2206038
- CDC — Adult Obesity Facts (41.9% US prevalence per NHANES 2017–March 2020): cdc.gov/obesity/adult-obesity-facts
- LegitScript — Independent verification of Cora Health certification status: legitscript.com/websites/?checker_keywords=trycora.io
- Pharmacy Compounding Accreditation Board (PCAB) — Hallandale Pharmacy is PCAB-accredited: achc.org/programs/pcab/
- NPPES — National Plan and Provider Enumeration System (verify Michael Wasef, MD): npiregistry.cms.hhs.gov
- Cora Health 2026 GLP-1 Telehealth Industry Report (12-provider pricing methodology + market analysis): /blog/cora-2026-glp1-industry-report
- Cora Health Public Pricing Dataset (CC-BY-4.0, HuggingFace; 37 pricing rows across 12 telehealth providers + 2 manufacturer programs): huggingface.co/datasets/cora-health/telehealth-glp1-pricing
- Cora Health Pharmacy Partners (details on Hallandale Pharmacy + VialsRx): trycora.io/pharmacy-partners
Cora Health Content Team
Written by the Cora Health content team. This article was medically reviewed by Michael Wasef, MD, a board-certified internal medicine physician at Wasef Health, PC, for clinical accuracy and compliance with current guidelines. Sections revised after the review date are not covered by that review; see the editor's note at the top of this article. Compounded medications are not FDA-approved.
Related reading
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new medication or treatment. Cora Health does not prescribe medication; licensed providers at Wasef Health, PC review every patient assessment and prescribe only when clinically appropriate.
Ozempic®, Wegovy®, Mounjaro®, Zepbound® and other brand names are registered trademarks of their respective owners; Cora Health is not affiliated with Novo Nordisk or Eli Lilly.
Begin your wellness journey today
Personalized wellness plans from licensed providers. Free shipping. 100% online.
See If You Qualify